Esketamine monotherapy efficacious in treatment‐resistant depression
The Brown University Psychopharmacology Update November 1, 2025 DOI: 10.1002/pu.31369 (opens in new tab)
Summary
AI-generated from the abstractIn adults with treatment-resistant depression, a 4-week trial found that intranasal esketamine given twice weekly at doses of 56 and 84 mg significantly improved depressive symptoms compared with placebo. Both doses outperformed placebo in this post-marketing trial, published online July 2, 2025, in JAMA Psychiatry.
Study at a glance
| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Population | Adults with treatment-resistant depression |
| Intervention | Intranasal esketamine |
| Dose | 56 and 84 mg |
| Duration | 4-week trial |
| Key finding | Twice-weekly intranasal esketamine at 56 and 84 mg significantly improved depressive symptoms compared with placebo in adults with treatment-resistant depression. |
Abstract
Twice‐weekly dosing of intranasal esketamine resulted in significant improvement in depressive symptoms compared with placebo in adults with treatment‐resistant depression, a 4‐week trial has found. Esketamine doses of 56 and 84 mg both outperformed placebo in the post‐marketing trial. Study results were published online July 2, 2025, in JAMA Psychiatry.